---
title: "Devonian Reported Distribution Agreement Termination"
date: "2025-02-10 19:00:09"
summary: "Devonian Health Group Inc. , a clinical stage corporation focused on developing unique solutions to inflammatory diseases, that saw its shares jump near 14% during regular trading hours on Friday, after trade Friday announced that its pharmaceutical distribution division, Altius Healthcare Group L.P., had been informed that one of its..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Devonian Health Group Inc. , a clinical stage corporation focused on developing unique solutions to inflammatory diseases, that saw its shares jump near 14% during regular trading hours on Friday, after trade Friday announced that its pharmaceutical distribution division, Altius Healthcare Group L.P., had been informed that one of its licensor does not intend to exercise its contractual license renewal option for the distribution of Dexlansoprazole for an additional term.

Friday's statement noted revenue for Dexlansoprazole represented 86% and 92% of Devonian's total reported revenues for fiscal year ended July 31, 2024, and quarter ended October 31,2024, respectively. The corporation said it will continue selling Dexlansoprazole until April 17, 2025, when the licence agreement will end, and will continue to sell Pantoprazole Magnesium and Cleo-35 thereafter.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250210:A3313141:0/)
